Avivagen Performance dei guadagni passati
Il passato criteri di controllo 0/6
Avivagen has been growing earnings at an average annual rate of 28.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 77.1% per year.
Informazioni chiave
28.4%
Tasso di crescita degli utili
28.8%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 6.0% |
Tasso di crescita dei ricavi | 77.1% |
Rendimento del capitale proprio | n/a |
Margine netto | -648.7% |
Ultimo aggiornamento sui guadagni | 31 Jul 2023 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Recent updates
Ripartizione dei ricavi e delle spese
Come Avivagen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Jul 23 | 1 | -5 | 3 | 0 |
30 Apr 23 | 1 | -6 | 4 | 0 |
31 Jan 23 | 1 | -6 | 5 | 0 |
31 Oct 22 | 1 | -6 | 5 | 0 |
31 Jul 22 | 0 | -6 | 5 | 0 |
30 Apr 22 | 1 | -6 | 5 | 0 |
31 Jan 22 | 1 | -7 | 5 | 0 |
31 Oct 21 | 1 | -6 | 5 | 0 |
31 Jul 21 | 2 | -6 | 4 | 0 |
30 Apr 21 | 1 | -5 | 4 | 0 |
31 Jan 21 | 1 | -5 | 4 | 0 |
31 Oct 20 | 1 | -5 | 4 | 0 |
31 Jul 20 | 1 | -5 | 5 | -1 |
30 Apr 20 | 1 | -5 | 5 | 0 |
31 Jan 20 | 1 | -5 | 5 | 0 |
31 Oct 19 | 1 | -5 | 4 | 0 |
31 Jul 19 | 1 | -5 | 4 | 1 |
30 Apr 19 | 1 | -5 | 4 | 1 |
31 Jan 19 | 1 | -5 | 4 | 1 |
31 Oct 18 | 1 | -5 | 4 | 1 |
31 Jul 18 | 1 | -5 | 4 | 1 |
30 Apr 18 | 1 | -5 | 4 | 1 |
31 Jan 18 | 0 | -5 | 4 | 1 |
31 Oct 17 | 0 | -5 | 4 | 1 |
31 Jul 17 | 0 | -4 | 4 | 1 |
30 Apr 17 | 0 | -4 | 3 | 1 |
31 Jan 17 | 0 | -3 | 2 | 1 |
31 Oct 16 | 0 | -3 | 2 | 1 |
31 Jul 16 | 0 | -3 | 2 | 1 |
30 Apr 16 | 0 | -2 | 2 | 1 |
31 Jan 16 | 0 | -2 | 2 | 1 |
31 Oct 15 | 0 | -2 | 2 | 1 |
31 Jul 15 | 0 | -2 | 2 | 1 |
30 Apr 15 | 0 | -2 | 2 | 1 |
31 Jan 15 | 0 | -2 | 2 | 1 |
31 Oct 14 | 0 | -2 | 2 | 1 |
31 Jul 14 | 0 | -2 | 2 | 0 |
30 Apr 14 | 0 | -2 | 2 | 0 |
31 Jan 14 | 0 | -2 | 2 | 0 |
Guadagni di qualità: VIVX.F is currently unprofitable.
Margine di profitto in crescita: VIVX.F is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Insufficient data to determine if VIVX.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerare la crescita: Unable to compare VIVX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: VIVX.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendimento del capitale proprio
ROE elevato: VIVX.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.